NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LyGenesis

LyGenesis

Private
Pittsburgh, PennsylvaniaHealthcare & Life Scienceshttps://www.lygenesis.com/

Last Round

Series A

Extension

Oct 24, 2023

Total Funding Raised

$37M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

LyGenesis is a clinical-stage biotechnology company developing cell therapies that use a patient's lymph nodes as bioreactors to regrow functioning ectopic organs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyregenerative medicineorgan regenerationgrowing organsbioreactorallogeneic cell therapyectopic organbiotechorgan failureclinical stage biotechorgan transplant alternativebioengineeringin vivo bioreactortissue engineeringtranslational research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LyGenesis Comparables

Compare LyGenesis with similar companies based on industry and business-model similarity.

LyGenesis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Satellite Bio
81%
Morphocell Technologies
80%
HepaTx Corporation
80%

LyGenesis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionOct 24, 2023
Convertible DebtDec 30, 2020
Convertible DebtOct 21, 2019
Series AMay 9, 2018

Key People

Founding team and executive leadership

Michael Hufford

Co-Founder And CEO

Founding Team

LyGenesis Investors

Notable investors and investment history

LyGenesis investors
InvestorRounds
Longevity Vision FundConvertible Debt
Prime Movers LabSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 78% MoM.

  • Dec 30, 2020

    $11M round led by Longevity Vision Fund and Juvenescence

LyGenesis Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LyGenesis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LyGenesis's valuation, stock price, and market status.

Firmographic Details

HeadquartersPittsburgh, Pennsylvania
Employee Range8
Year Founded2017
Last FundingOct 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.